PredictAD

Dementia causes long and oppressive suffering to patients and their relatives and imposes enormous costs on society. About 25 million people suffered from dementia in 2000. As a 4-fold increase of this number is expected by 2050, dementia is one main health issue of the next decades.

Alzheimer's disease (AD) covers 60-70% of all dementia cases. No cure for AD exists, and effective and reliable early diagnostic techniques are lacking. Early diagnosis and progress monitoring of AD is a central part of treatment once future drugs and prevention strategies become available. There is a strong indication that different biomarkers provide a reliable and early indication of AD prior to its major clinical signs. However, optimal early diagnosis requires information from a combination of different biomarkers to be used in a clinically useful way.

The objective of PredictAD is 1) to find the best combination of biomarkers for AD diagnostics from heterogeneous data (imaging, electrophysiology, molecular level, clinical tests, demographics) and 2) to develop clinically useful tools integrating the optimal biomarker results. Comprehensive biomarker discovery techniques and rigorous statistical models will be developed using the consortium's large databases. The accuracy and usability of models and tool will be clinically evaluated. The cost-effectiveness of heterogeneous data in AD diagnostic procedures will be studied.

By reaching its objectives, PredictAD provides an efficient and reliable solution for early AD diagnosis in clinical practice. The impacts on patients, their relatives and society are reduced suffering and costs. As we are living in the dawn of an era of new drugs and prevention strategies combined with increasing AD prevalence, now is the time to exploit the vast potential of information hiding in heterogeneous patient databases. PredictAD combines the best forces in Europe to solve the AD diagnostics problem, and hence strengthens EU leadership on the market.

For further information, please visit:
http://www.predictad.eu

Project co-ordinator:
Valtion teknillinen tutkimuskeskus VTT

Partners:

  • Nexstim Oy
  • Imperial College of Science, Technology and Medicine
  • Rigshospitalet
  • Kuopion yliopisto
  • Università degli Studi di Milano
  • GE Healthcare Ltd.
  • Uppsala universitet

Timetable: from 06/2008 – to 05/2011

Total cost: € 3.981.565

EC funding: € 2.891.526

Programme Acronym: FP7-ICT

Subprogramme Area: Virtual physiological human

Contract type: Collaborative project (generic)


Related news article:

Most Popular Now

Merck and Tencent Announce Collaboration…

Merck, a leading science and technology company, signed a strategic collaboration agreement with Tencent, a leading provider of Internet value added services. The collaboration will primarily focus on increasing public...

Merck Granted U.S. Patent for Novel Comb…

Merck, a leading science and technology company, today announced that it has been granted Patent No. US 10,193,695 by the United States Patent and Trademark Office (USPTO). The patent relates...

The European Health Catapult Program for…

Through dedicated sessions, a group of international top-level investors, key healthcare leaders and industry stakeholders work closely together challenging 40+ ambitious startups to optimize their business plan and strengthen their...

Applications Now Open for Pioneering Dig…

The Yorkshire & Humber AHSN (Academic Health Science Network), in partnership with mHabitat, announces that applications for the 2019 Propel@YH digital health accelerator programme are now open. Propel@YH has been...

Flagship Axe the Fax Trust Rolls out Hyb…

Leeds Teaching Hospitals NHS Trust (LTHT), the organisation at the forefront of the national Axe the Fax campaign, is implementing an electronic fax solution to tackle its last remaining machines...

First EU Citizens Using ePrescriptions i…

The first EU patients can use digital prescriptions issued by their home doctor when visiting a pharmacy in another EU country: Finnish patients are now able to go to a...

Boehringer Ingelheim (Canada) Ltd. and I…

Boehringer Ingelheim (Canada) Ltd. and IBM Canada announced at the Healthcare Information and Management Systems Society (HIMSS) conference in Orlando, Florida, their plans to explore the use of blockchain technology...

Final Report: Provision of a Market Stud…

The aim of the study is to examine the telemedicine market in Europe and to understand the factors that determine its development. The analysis maps telemedicine applications and solutions, and...

Open Access Drug Development Tools Featu…

New open access tools for drug development, obesity, and the environmental impacts of medicines are the focus of a new IMI2 Call for proposals launched today. The total budget of...

The NHS Long Term Plan: Cracking the Da …

Opinion Article by Prof. Michael Thick, Chief Medical Officer, Chief Clinical Information Officer, IMS MAXIMS Reading the NHS Long Term Plan this week, I had a definite sense of déjà vu...

Big Data Approach Shown to be Effective …

Researchers at Rensselaer Polytechnic Institute who developed a blood test to help diagnose autism spectrum disorder have now successfully applied their distinctive big data-based approach to evaluating possible treatments. The...

Highland Marketing Advisory Board Respon…

The first meeting of Highland Marketing's newly expanded advisory board discussed the NHS Long Term Plan and what will be needed to make it a success. Structural change, leadership, investment...